Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
04 oct. 2023 09h00 HE
|
Clearside Biomedical, Inc.
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
03 oct. 2023 16h35 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
19 sept. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO,...
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
02 août 2023 16h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023
01 août 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting
31 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Suprachoroidal Injection of CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months - ALPHARETTA, Ga., July 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
20 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
17 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Evaluating CLS-AX as a Potential Twice-a-Year Therapy - - Trial Progressing with Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., July 17, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
11 juil. 2023 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...